CONFERENCE REPORTER
In the double-blind induction phase of the randomized, active-controlled, phase 3 TRANSFORM-2 study (NCT02418585), investigators explored early dose management and up-titration from 56 to 84 mg of esketamine for…
CONFERENCE REPORTER
In the double-blind induction phase of the randomized, active-controlled, phase 3 TRANSFORM-2 study (NCT02418585), investigators explored early dose management and up-titration from 56 to 84 mg of esketamine for…